SUPPORTİNG THE WRİTİNG SKİLLS OF PRİMARY SCHOOL THİRD GRADE GİFTED STUDENTS WİTH ACTİVİTY-BASED DİGİTAL STORYTELLİNG: ACTİON RESEARCH

The aim of this research is to find out how activity-based digital storytelling affects the writing and digital storytelling-making skills of gifted students. In this research, which is designed as an action research, the researcher was the practitioner and also the conductor of the research. The research was conducted in the first semester of the 2018-2019 academic year in the Science and Art Center, where talented students were studying. The study group consists of 7 gifted third-grade students who continue the support education program. The implementation of the action plan took 10 weeks. The data were collected by Student Information Form, 6 + 1 Analytical Writing and Evaluation Scale, Digital Storytelling Evaluation Rubric, interview forms, researcher and student diary. According to the results of the study, the action plan applied improved the writing skills of the students. It was observed that the writing skills of the students improved according to the scores of the students during the pre-evaluation and final evaluation and application process. It was seen that the digital story formation skills of the students improved during the pre-evaluation and final evaluation and application process. According to the opinions of the students, it was determined that with the activity-based digital storytelling activities, the students learned how to write the text types, they liked writing and they found the studies entertaining and these studies improved their writing skills. In addition, it was that writing activities make writing easier, develop imagination, and digital storytelling studies also helped to see and correct errors in writing, and to write more attentive and carefully. In this study, in which action research was used, as the results are not generalized, the activity-based digital storytelling studies can be applied with different methods and the results can be investigated. Additionally, application oriented research can be increased to improve the writing skills of gifted students.  Article visualizations

Hot Air Drying of Green Table Olives

The characteristics of hot air-drying of green table olives (Domat variety) by using a tray dryer were studied. Air temperature varied from 40 to 70 °C with an air velocity of 1 m/s. Drying rate curves were determined and quality of dried green olives was evaluated by instrumental analysis (bulk density, particle density, porosity, shrinkage, moisture content, water activity, colour value, protein content, oil content, peroxide value and acidity). Consumers’ acceptance test and microbiological analysis were also applied

Hot Air Drying of Green Table Olives

The characteristics of hot air-drying of green table olives (Domat variety) by using a tray dryer were studied. Air temperature varied from 40 to 70 °C with an air velocity of 1 m/s. Drying rate curves were determined and quality of dried green olives was evaluated by instrumental analysis (bulk density, particle density, porosity, shrinkage, moisture content, water activity, colour value, protein content, oil content, peroxide value and acidity). Consumers’ acceptance test and microbiological analysis were also applied

Učinci liječenja hidroksiklorokinomplus favipiravirom na klinički tok i biomarkeri u hospitaliziranih pacijenata s COVID-19 i upalom pluća

Background: The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia. Unfortunately, the optimal treatment approach is still uncertain. However, many studies have been conducted on the effectiveness of several medications in the treatment of COVID-19 infection. The aim of this study was to evaluate the effectiveness of the hydroxychloroquine (HCQ) + favipiravir (FAV) treatment regimen and HCQ alone by comparing the patient’s clinical response and laboratory results on the fifth day of treatment in patients hospitalized due to COVID-19 infection. Patients and methods: This retrospective cohort study was conducted in Malatya Training and Research Hospital between March 2020 and July 2020. The study included 69 patients with confirmed COVID-19 with pneumonia. The patients were divided into 2 groups, those receiving HCQ alone and those receiving the HCQ + FAV combination. Results: A total of 69 patients were included in the study, and the mean age was 60.09±15.56 years. A statistically significant decrease was observed in C-reactive protein (CRP) levels, at the end of the fifth day, in patients who received HCQ + FAV treatment (p=0.002), whereas there was no decrease in CRP levels in patients who received HCQ treatment alone. In addition, an increase in lymphocyte count and a better fever response was observed at the end of the fifth day in patients who received HCQ + FAV (p=0.008). However, there was no statistical difference between both treatment regimens in terms of hospital stay and treatment results (p=0.008, p=0.744, p=0.517). Conclusion: Although the combination of HCQ + FAV treatment was observed to be effective on CRP levels and fever response in patients with COVID-19 pneumonia, there was no difference in terms of hospital stay and discharge.Pozadina: Bolest uzrokovana novim koronavirusom 2019 (COVID-19) ima širok spektar kliničkih manifestacija, pri čemu je upala pluća najčešća ozbiljna klinička manifestacija infekcije koronavirusom. Nažalost, optimalni pristup liječenju još uvijek nije jasno utvrđen. Ipak, provedeno je mnogo studija koje su istraživale učinkovitost raznih lijekova u liječenju infekcije COVID-19 virusom. Cilj ove studije bio je utvrditi učinkovitost liječenja kombinacijom hidroksiklorokina (HCQ) i favipiravira (FAV) te liječenja isključivo HCQ-om, uspoređivanjem kliničkog odgovora pacijenata na liječenje i njihovih laboratorijskih rezultata nakon pet dana liječenja u pacijenata hospitaliziranih zbog infekcije virusom COVID-19. Pacijenti i metode: Ova retrospektivna kohortna studija provedena je u Malatya Training and Research Hospital između ožujka 2020. i srpnja 2020. Uključivala je 69 pacijenata s potvrđenom infekcijom virusa COVID-19 sa upalom pluća. Pacijenti su podijeljeni u dvije skupine, od kojih je jedna primala samo HCQ, a druga kombinaciju HCQ + FAV. Rezultati: U studiju je uključeno ukupno 69 pacijenata s prosječnom dobi od 60,09±15,56 godina. Zamijećena je statistički značajno smanjenje u razini C-reaktivnog proteina (CRP) na kraju petog dana liječenja u pacijenata koji su primali HCQ + FAV (p=0,002), a nije bilo smanjenja u razini CRP-a u pacijenata koji su primali samo HCQ. Uz to, u pacijenata koji su primali HCQ + FAV zamijećeno je i povećanje u broju limfocita te bolji odgovor na vrućicu na kraju petog dana liječenja (p=0,008). Ipak, nije bilo statističke razlike između ta dva režima liječenja u odnosu na trajanje hospitalizacije i rezultata liječenja (p=0,008, p=0,744, p=0,517). Zaključak: Iako je kombinacija HCQ + FAV bila učinkovita glede razine CRP-a i odgovora na vrućicu u pacijenata sa upalom pluća uzrokovanom COVID-19 virusom, nije bilo razlike u trajanju hospitalizacije i otpusta iz bolnice

Investigation of the relationship between type 2 diabetes risk and night eating behavior

The aim of this study is to determine the prevalence of night-eating behavior and risk of undiagnosed type 2 diabetes in the community and to investigate a relationship between them. The study was carried out on 1381 individuals, aged 18-80 years, and living in Malatya province, between February-March 2018. The questionnaire consisting of socio-demographic characteristics, FINDRISK scale and Night Eating Scale was applied by face-to-face interview technique. The data were evaluated by using the SPSS 22.0 program. Significance level was accepted as p [Med-Science 2020; 9(2.000): 408-12

Evaluation of soluble CD200 levels in type 2 diabetic foot and nephropathic patients: Association with disease activity

Background: CD200 (OX-2) is a novel immune-effective molecule, existing in a cell membrane-bound form, as well as in a soluble form in serum (s OX-2), which acts to regulate inflammatory and acquired immune responses

The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success

Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor

Objective: To evaluate the possible neutropenia-related effects of administering adriamycin [doxorubicin], bleomycin, vinblastin, dacarbazine (ABVD) chemotherapy in Hodgkin’s lymphoma patients with moderate or severe neutropenia without granulocyte-colony stimulating factor supplementation. Methods: This study evaluated neutropenia-related outcomes and the need for granulocyte-colony stimulating factor use during the periods between chemotherapy rounds. Forty-three rounds of ABVD chemotherapy were evaluated in the study. The outcomes that could be related to neutropenia were analyzed. In addition, rounds of ABVD chemotherapy given in the presence of severe neutropenia were compared with ABVD chemotherapy rounds given in the presence of moderate neutropenia in terms of neutropenia-related outcomes and the need for granulocyte-colony stimulating factor use. The study only included patients with classical Hodgkin's disease (lymphoma). Patients with a final neutrophil count of 0.05). Furthermore, none of the patients included in the study had bleomycin-related lung toxicity during the treatment periods included in the study. Conclusion: Administering ABVD chemotherapy to patients with moderate neutropenia seems to be safe

Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study

Certain genetic mutations could have a role in the etiology of acute myeloid leukemia (AML). Hereby, in this study, we primarily aimed to investigate the distribution of genetic mutations in AML patients. We also attempted to analyze the incidence of genetic mutations in AML patients from Turkey.This retrospective study included a total of 126 patients diagnosed with AML, who had molecular mutation test results or records in their patient files. The patients who were not citizens of the Republic of Turkey were not included in the study.It was observed that analyses for at least 1 c-kit exon mutation had been carried out on 76 patients, which detected no c-kit mutation among the types of genetic mutations investigated in all of those 76 patients. We found the frequency of FMS-like tyrosine kinase 3-internal tandem duplication mutation as 25%. The prevalence of translocation(15;17) was approximately 11% and the prevalence of translocation(8;21) was % 6.25. In addition, we also showed that the frequency of inversion16 was nearly 3.7%.Lastly, the possibility of c-kit mutation in AML patients from Turkey might actually be low